An Essay Discussing Budd-Chiari Syndrome
DOI:
https://doi.org/10.37591/rrjooh.v12i2.3266Keywords:
Budd-Chiari syndrome, hepatomegaly, disorders, abdominal, ascites, thrombosis, sinusoidal obstruction, pericardial disease, veno-occlusive disease, rokitansky’s disease.Abstract
Budd-Chiari syndrome (BCS) is defined as hepatic venous outflow tract obstruction, independent of the level or mechanism of obstruction, provided the obstruction is not due to cardiac disease, pericardial disease, or sinusoidal obstruction syndrome (veno-occlusive disease). Primary Budd-Chiari syndrome is present when there is obstruction due to a predominantly venous process (thrombosis or phlebitis), whereas secondary Budd-Chiari is present when there is compression or invasion of the hepatic veins and/or the inferior vena cava by a lesion that originates outside of the vein, for example: malignancy. The onset of Budd-Chiari syndrome happens over an extended time, or it occurs very suddenly. Some people with this syndrome have more veins that are affected, or the affected veins are in more difficult areas of the liver; these individuals have more serious form of the syndrome than those with fewer veins impacted in the liver. Budd-Chiari Syndrome is also known as Hepatic Veno-Occlussive Disease, Budd’s Syndrome, and Rokitansky’s Disease.References
Ferral H, Behrens G, Lopera J. Budd-Chiari syndrome. Am J Roentgenol (AJR). 2012 Oct; 199(4): 737–45. doi: 10.2214/AJR.12.9098. PMID: 22997363.
Aydinli M, Bayraktar Y. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis. World J Gastroenterol. 2007 May 21; 13(19): 2693–6. doi: 10.3748/wjg.v13.i19.2693. PMID: 17569137; PMCID: PMC4147117.
Horn Christian L, Amilcar Morales, Savard Christopher E, Farrell Geoffrey C, Ioannou George N. Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH. Hepatol Commun. 2021 Aug 24; 6(1): 12–35. https://doi.org/10.1002/hep4.1801.
Babu Lal Meena. (2019 Jan 18). Hepatitis B Infection. [Online]. Icliniq. https://www.icliniq. com/articles/liver-diseases/acute-and-chronic-hepatitis-b-infection.
Michelle Lai (MD, MPH). (2019 Jan 18). Budd Chiari Syndrome. [Online]. [cited on 2023 April 06] Available from: Medilib.ir. “مدیلیبیلدب م .” MediLib, 2023. https://medilib.ir/uptodate/show/3562.
Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009 Jan; 50(1): 195–203. doi: 10.1016/j.jhep.2008.10.007. Epub 2008 Oct 26. PMID: 19012988.
Abdel Hameed MR, Elbeih EAS, Abd El-Aziz HM, Afifi OA, Khalaf LMR, Ali Abu Rahma MZ, Sabry A. Epidemiological Characteristics and Etiology of Budd-Chiari Syndrome in Upper Egypt. J Blood Med. 2020 Dec 30; 11: 515–524. doi: 10.2147/JBM.S278678. PMID: 33408545; PMCID: PMC7779296.
Carvalho DT, Oikawa FT, Matsuda NM, Évora PR, Yamada AT. Budd-Chiari syndrome in a 25-year-old woman with Behçet's disease: a case report and review of the literature. J Med Case Rep. 2011; 5(1): 1–4.
Stanciugelu A, Petrică A, Chiriac SD, Iurciuc M, Boruga MV, Balica N, Mederle OA. A rare encounter with two cases of Budd-Chiari syndrome in the Emergency Department: A case report. Exp Ther Med. 2022; 24(6): 1–5.
Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000 Mar; 31(3): 587–91. doi: 10.1002/hep.510310307. PMID: 10706547.
Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000 Oct 1; 96(7): 2364–8. PMID: 11001884.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
